東光化工(01702.HK)年度純利增112.4%至2.66億元 末期息10港仙
格隆匯3月25日丨東光化工(01702.HK)公佈,截至2021年12月31日止12個月,公司收益為28.81億元人民幣,同比增長47.28%;公司擁有人應占溢利2.66億元,同比增長112.40%;每股盈利42.9分,擬派末期股息每股普通股10港仙。
集團收入同比增長47.3%,主要由於尿素產品平均售價上升。於報吿期間,集團尿素產品平均售價約每噸人民幣2,022元,較2020年12月31日止年度約每噸人民幣1,495元上升約35.3%。由於報吿期間收入上升,以及收入百分比增幅高於銷售成本百分比增幅,集團毛利及毛利率亦於報吿期間有所上升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.